[시장보고서]전신경화증 치료 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

전신경화증 치료 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Systemic Scleroderma Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

상품코드 : 1470700

리서치사 : Persistence Market Research

발행일 : 2024년 04월

페이지 정보 : 영문 380 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,224,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,550,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,286,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

이 조사 보고서는 세계 전신경화증 치료 시장에 대한 상세한 분석을 제공합니다. 이 종합적인 보고서는 주요 시장 역학, 성장 촉진요인, 과제 및 신흥 동향에 대한 귀중한 인사이트를 제공합니다. 헬스케어 산업의 전신경화증 치료 부문에 대한 자세한 개요를 제공하고 2024년부터 2031년까지 시장 성장 궤적을 예측하는 독점 데이터와 통계를 제시합니다.

주요 인사이트

전신경화증 치료 시장 규모(2024년) : 12억 달러
예상 시장 가치(2031년) : 41억 5,000만 달러
세계 시장 성장률(2024-2031년 CAGR) : 8.0%

전신경화증 치료 시장 - 보고서 범위:

전신경화증 치료 시장은 전신경화증으로 알려진 전신성 경화증의 증상과 합병증을 관리하기 위한 의약품, 생물학적 제제 및 지지 요법 개입을 포괄하는 광범위한 시장입니다. 이 자가면역질환은 여러 장기와 조직에 영향을 미치며 섬유화, 혈관 기능 장애, 면역 이상 등을 유발합니다. 시장 개발 이해관계자에는 의료 서비스 제공자, 제약회사, 학술 연구 기관, 환자 지원 단체 등이 포함되며, 전신경화증 환자를 위한 효과적인 치료 옵션을 개발 및 제공하기 위해 협력하고 있습니다. 시장 성장의 원동력은 유병률 증가, 치료법 발전, 개인 맞춤형 의료 및 환자 중심 치료에 대한 강조가 증가하고 있습니다.

시장 촉진요인:

세계 전신경화증 치료 시장은 몇 가지 주요 시장 촉진요인의 혜택을 받고 있습니다. 전신경화증에 대한 인식이 높아지고 진단 기술이 향상됨에 따라 질병의 조기 발견 및 진단에 기여하여 적시에 개입하고 치료를 시작할 수 있습니다. 또한, 면역학, 분자생물학 및 표적 치료의 발전은 섬유화, 염증 및 자가면역에 관여하는 특정 경로를 다루는 전신경화증 관리를 위한 새로운 약리학 및 생물학적 제제의 개발로 이어졌습니다. 또한, 공동 연구, 임상시험 및 환자 등록은 전신경화증 바이오마커, 예측 인자 및 치료 표적의 발견과 검증을 촉진하여 기술 혁신과 시장 확장을 촉진하고 있습니다.

시장 억제요인:

전신경화증 치료 시장은 큰 성장이 기대되는 시장이지만, 질병의 불균일성, 치료의 편차, 환자 결과에 대한 도전에 직면해 있습니다. 전신경화증은 국소 피부 강피증에서 미만성 피부 강피증에 이르기까지 다양한 임상 표현형 스펙트럼을 포함하며, 각기 다른 병태생리학적 기전과 치료 반응에 따라 달라질 수 있습니다. 이러한 이질성은 질병 관리와 치료 정책 결정을 복잡하게 만들고, 치료 결과와 환자 반응에 차이를 가져옵니다. 또한, 질환의 병인 및 진행에 대한 이해가 부족하고, 임상시험 설계 및 평가변수 선택에 대한 이해 부족으로 인해 새로운 전신강직성피부염 치료제의 개발 및 승인에 어려움을 겪고 있습니다. 이러한 문제를 해결하기 위해서는 다학제적 협력, 환자 계층화 전략, 적응증별 시험 설계를 통해 치료 효과를 최적화하고 전신경화증 환자의 치료를 개별화할 수 있는 방안이 필요합니다.

시장 기회:

전신경화증 치료 시장은 기술 혁신, 협업, 환자 중심 치료 모델로 인해 큰 성장 기회를 맞이하고 있습니다. 정밀의료, 바이오마커 탐색, 디지털 헬스 기술 등의 새로운 트렌드는 전신강직성 경화증 환자의 개인화된 진단, 치료, 모니터링에 새로운 길을 열어줄 것입니다. 새로운 치료 표적, 질병 조절 약물 및 병용요법의 발굴은 다양한 전신강직성 경화증 아형과 병기에 대해 보다 효과적이고 표적화된 치료 요법을 개발할 수 있게 해줍니다. 또한 환자 참여, 옹호 및 교육 이니셔티브는 전신경화증 환자들이 적극적으로 치료에 참여하고 치료 순응도를 높이며 건강 결과를 개선할 수 있도록 돕습니다. 전략적 파트너십, 연구 컨소시엄 및 규제 혜택은 과학적 발견을 임상적으로 의미 있는 치료법으로 전환하는 것을 촉진하고 전신강피증 관리의 혁신과 시장 성장을 촉진합니다.

본 보고서에서 다루는 주요 질문들

전세계 전신경화증 치료 시장의 성장을 촉진하는 요인은 무엇인가?
면역학, 분자생물학, 표적치료의 발전은 전신강직성피부염의 치료 상황을 어떻게 변화시키고 있는가?
전신경화증 부문에서 의료 서비스 제공자와 제약회사가 직면한 주요 과제와 기회는 무엇인가?
전신경화증 관리에서 환자 예후를 개선할 가능성이 가장 높은 치료법과 치료 표적은 무엇인가?
미충족 수요에 대응하고 전신경화증 치료 시장에서 혁신을 촉진하기 위해 주요 기업들은 어떤 전략을 채택하고 있는가?

소개/주요 조사 결과
과거 시장 분석(금액), 2019-2023년
현재 및 향후 시장 예측(금액), 2024-2031년
- 약물 테라피
  - 코르티코스테로이드
  - 면역억제제
  - 비스테로이드성 항염증제
  - 칼슘 채널 차단제
  - 양성자 펌프 억제제
  - TNF 억제제
  - 엔도텔린 수용체 길항제
  - 포스포디에스테라제 5억제제
  - 안지오텐신전환효소
  - 조혈모세포 이식(HSCT)
타겟 장기별 시장 매력도 분석

제10장 전신경화증 치료 세계 시장 분석과 예측, 투여 경로별

소개/주요 조사 결과
과거 시장 분석(금액), 2019-2023년
현재 및 향후 시장 예측(금액), 2024-2031년
- 주사
- 경구
- 외용
투여 경로별 시장 매력도 분석

제11장 전신경화증 치료 세계 시장 분석과 예측, 유통 채널별

소개/주요 조사 결과
과거 시장 분석(금액), 2019-2023년
현재 및 향후 시장 예측(금액), 2024-2031년
- 병원 약국
- 전문 클리닉
- 소매 약국
- 온라인 약국
유통 채널별 시장 매력도 분석

제12장 전신경화증 치료 세계 시장 분석과 예측, 지역별

소개
과거 시장 규모(금액) 분석,2019-2023년
현재 시장 규모(금액) 분석과 예측, 2024-2031년
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(MEA)
지역별 시장 매력도 분석

제13장 북미 전신경화증 치료 시장 분석과 예측

제14장 라틴아메리카의 전신경화증 치료 시장 분석과 예측

제15장 유럽 전신경화증 치료 시장 분석과 예측

제16장 남아시아의 전신경화증 치료 시장 분석과 예측

제17장 동아시아 전신경화증 치료 시장 분석과 예측

제18장 오세아니아 전신경화증 치료 시장 분석과 예측

제19장 중동 및 아프리카(MEA)의 전신경화증 치료 시장 분석과 예측

제20장 시장 구조 분석

기업 계층별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석

제21장 경쟁 분석

경쟁 대시보드
경쟁 벤치마크
경쟁 상세
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Sanofi SA
- Lupin Ltd
- Cipla Ltd
- Teva Pharmaceuticals
- Johnson & Johnson Services Inc.
- Bayer Healthcare LLC
- F. Hoffmann-La Roche Ltd
- Amgen Inc
- Zydus Lifesciences Ltd
- Casper Pharma
- Boehringer Ingelheim Pharmaceuticals, Inc
- Organon LLC
- Accord Healthcare Inc

제22장 사용되는 가정과 두문자어

제23장 조사 방법

ksm

영문 목차

영문목차

Persistence Market Research, a renowned market research firm, has conducted an exhaustive analysis of the global Systemic Scleroderma Treatment Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the systemic scleroderma treatment segment within the healthcare industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2031.

Key Insights:

Systemic Scleroderma Treatment Market Size (2024): US$ 1.20 Bn
Projected Market Value (2031): US$ 4.15 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 8.0%

Systemic Scleroderma Treatment Market - Report Scope:

The Systemic Scleroderma Treatment Market encompasses a wide range of pharmaceuticals, biologics, and supportive care interventions aimed at managing the symptoms and complications of systemic sclerosis, also known as systemic scleroderma. This autoimmune disease affects multiple organs and tissues, leading to fibrosis, vascular dysfunction, and immune dysregulation. Market stakeholders include healthcare providers, pharmaceutical companies, academic research institutions, and patient advocacy groups, collaborating to develop and deliver effective treatment options for systemic scleroderma patients. Market growth is driven by increasing disease prevalence, advancements in treatment modalities, and growing emphasis on personalized medicine and patient-centered care.

Market Growth Drivers:

The global Systemic Scleroderma Treatment Market benefits from several key growth drivers. Rising awareness about systemic sclerosis and improved diagnostic techniques contribute to the early detection and diagnosis of the disease, enabling timely intervention and treatment initiation. Moreover, advancements in immunology, molecular biology, and targeted therapies have led to the development of novel pharmacological agents and biologics for systemic scleroderma management, addressing specific pathways involved in fibrosis, inflammation, and autoimmunity. Additionally, collaborative research efforts, clinical trials, and patient registries facilitate the discovery and validation of biomarkers, predictive factors, and therapeutic targets for systemic scleroderma, driving innovation and market expansion.

Market Restraints:

Despite its significant growth prospects, the Systemic Scleroderma Treatment Market faces challenges related to disease heterogeneity, treatment variability, and patient outcomes. Systemic sclerosis encompasses a spectrum of clinical phenotypes, ranging from limited cutaneous scleroderma to diffuse cutaneous scleroderma, each with distinct pathophysiological mechanisms and treatment responses. This heterogeneity complicates disease management and therapeutic decision-making, leading to variability in treatment outcomes and patient responses. Moreover, limited understanding of disease etiology and progression, as well as gaps in clinical trial design and endpoint selection, hinder the development and regulatory approval of novel systemic scleroderma therapies. Addressing these challenges requires multidisciplinary collaboration, patient stratification strategies, and adaptive trial designs to optimize treatment efficacy and personalize care for systemic sclerosis patients.

Market Opportunities:

The Systemic Scleroderma Treatment Market presents significant growth opportunities driven by innovation, collaboration, and patient-centric care models. Emerging trends such as precision medicine, biomarker discovery, and digital health technologies offer new avenues for personalized diagnosis, treatment, and monitoring of systemic sclerosis patients. The identification of novel therapeutic targets, disease-modifying agents, and combination therapies enables the development of more effective and targeted treatment regimens for different systemic scleroderma subtypes and disease stages. Furthermore, patient engagement, advocacy, and education initiatives empower systemic sclerosis patients to actively participate in their care, enhance treatment adherence, and improve health outcomes. Strategic partnerships, research consortia, and regulatory incentives facilitate the translation of scientific discoveries into clinically meaningful therapies, driving innovation and market growth in systemic scleroderma management.

Key Questions Answered in the Report:

What factors are driving the growth of the Systemic Scleroderma Treatment Market globally?
How are advancements in immunology, molecular biology, and targeted therapies reshaping the treatment landscape of systemic sclerosis?
What are the key challenges and opportunities facing healthcare providers and pharmaceutical companies in the systemic scleroderma segment?
Which treatment modalities and therapeutic targets offer the highest potential for improving patient outcomes in systemic scleroderma management?
What strategies are leading companies employing to address unmet needs and drive innovation in the systemic scleroderma treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global Systemic Scleroderma Treatment Market, including pharmaceutical companies, biotechnology firms, and academic research centers, focus on innovation, collaboration, and patient-centricity to drive market growth and improve clinical outcomes. These companies invest in research and development to discover and develop novel therapies targeting key pathways implicated in systemic sclerosis pathogenesis, such as fibrosis, autoimmunity, and vascular dysfunction. Moreover, strategic partnerships with patient advocacy groups, academic consortia, and regulatory agencies enable companies to leverage patient insights, scientific expertise, and regulatory support for drug development and commercialization. Furthermore, emphasis on real-world evidence generation, patient-reported outcomes, and health economic analyses enhances value proposition and market access for systemic scleroderma therapies.

Key Companies Profiled:

Pfizer Inc.
Novartis AG
GlaxoSmithKline plc.
Sanofi SA
Lupin Ltd
Cipla Ltd
Teva Pharmaceuticals
Johnson & Johnson Services Inc.
Bayer Healthcare LLC
F. Hoffmann-La Roche Ltd
Amgen Inc
Zydus Lifesciences Ltd
Casper Pharma
Boehringer Ingelheim Pharmaceuticals, Inc
Organon LLC
Accord Healthcare Inc

Systemic Scleroderma Treatment Market Research Segmentation:

Systemic Scleroderma Treatment Market by Target Organ:

Skin Fibrosis
Musculoskeletal
Digital Ulcers
Pulmonary Arterial Hypertension
Gastrointestinal
Pulmonary Fibrosis
Scleroderma Renal Crisis

Systemic Scleroderma Treatment Market by Treatment Type:

Drug Therapy
Corticosteroids
Immunosuppressants
Nonsteroidal Anti-Inflammatory Drugs
Calcium Channel Blockers
Proton Pump Inhibitors
TNF Inhibitors
Endothelin Receptor Antagonists
Phosphodiesterase Type 5 Inhibitors
Angiotensin-Converting Enzyme
Hematopoietic Stem Cell Transplantation (HSCT)

Systemic Scleroderma Treatment Market by Route of Administration:

Injectable Systemic Scleroderma Drugs
Oral Systemic Scleroderma Drugs
Topical Systemic Scleroderma Drugs

Systemic Scleroderma Treatment Market by Distribution Channel:

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
Online Pharmacies

Systemic Scleroderma Treatment Market by Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends

4. Key Success Factors

4.1. New Drug Approvals
4.2. Key Strategies Followed By Manufacturers
4.3. Drug Adoption / Usage Analysis
4.4. Regulatory Scenario
4.5. Disease Epidemiology
4.6. Pipeline Assessment

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Per Capita Healthcare Expenditure Outlook
- 5.1.4. Global Pharmaceutical Market Outlook
- 5.1.5. Rare Disease Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Top Companies Historical Growth
- 5.2.2. Product Adoption Rate and Demand
- 5.2.3. New Product Launches
- 5.2.4. Increase in rate of skin diseases
- 5.2.5. Increase in air pollution
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Recovery Scenario - Short term, Midterm and Long Term Impact
6.4. COVID19 and Impact Analysis, 2023 Market Scenario

7. Global Systemic Scleroderma Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Target Organ

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Target Organ, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Target Organ, 2024-2031
- 8.3.1. Skin Fibrosis
- 8.3.2. Musculoskeletal
- 8.3.3. Digital Ulcers
- 8.3.4. Pulmonary Arterial Hypertension
- 8.3.5. Gastrointestinal
- 8.3.6. Pulmonary Fibrosis
- 8.3.7. Scleroderma Renal Crisis
8.4. Market Attractiveness Analysis, By Target Organ

9. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Therapy Type

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Therapy Type, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy Type, 2024-2031
- 9.3.1. Drug Therapy
  - 9.3.1.1. Corticosteroids
  - 9.3.1.2. Immunosuppressants
  - 9.3.1.3. Nonsteroidal Anti-Inflammatory Drugs
  - 9.3.1.4. Calcium Channel Blockers
  - 9.3.1.5. Proton Pump Inhibitors
  - 9.3.1.6. TNF Inhibitors
  - 9.3.1.7. Endothelin Receptor Antagonists
  - 9.3.1.8. Phosphodiesterase Type 5 Inhibitors
  - 9.3.1.9. Angiotensin-Converting Enzyme
  - 9.3.1.10. Hematopoietic Stem Cell Transplantation (HSCT)
9.4. Market Attractiveness Analysis, By Target Organ

10. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Route of Administration

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2031
- 10.3.1. Injectable
- 10.3.2. Oral
- 10.3.3. Topical
10.4. Market Attractiveness Analysis, By Route of Administration

11. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
- 11.3.1. Hospital Pharmacies
- 11.3.2. Specialty Clinics
- 11.3.3. Retail Pharmacies
- 11.3.4. Online Pharmacies
11.4. Market Attractiveness Analysis, By Distribution Channel

12. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Region

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis, By Region

13. North America Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Target Organ
- 13.3.3. By Therapy Type
- 13.3.4. By Route of Administration
- 13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Target Organ
- 13.4.3. By Therapy Type
- 13.4.4. By Route of Administration
- 13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Systemic Scleroderma Treatment Market
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Target Organ
    - 13.8.1.2.2. By Therapy Type
    - 13.8.1.2.3. By Route of Administration
    - 13.8.1.2.4. By Distribution Channel
- 13.8.2. Canada Systemic Scleroderma Treatment Market
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Target Organ
    - 13.8.2.2.2. By Therapy Type
    - 13.8.2.2.3. By Route of Administration
    - 13.8.2.2.4. By Distribution Channel

14. Latin America Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 14.3.1. By Country
  - 14.3.1.1. Brazil
  - 14.3.1.2. Mexico
  - 14.3.1.3. Rest of Latin America
- 14.3.2. By Target Organ
- 14.3.3. By Therapy Type
- 14.3.4. By Route of Administration
- 14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Target Organ
- 14.4.3. By Therapy Type
- 14.4.4. By Route of Administration
- 14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Brazil Systemic Scleroderma Treatment Market
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Target Organ
    - 14.8.1.2.2. By Therapy Type
    - 14.8.1.2.3. By Route of Administration
    - 14.8.1.2.4. By Distribution Channel
- 14.8.2. Argentina Systemic Scleroderma Treatment Market
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Target Organ
    - 14.8.2.2.2. By Therapy Type
    - 14.8.2.2.3. By Route of Administration
    - 14.8.2.2.4. By Distribution Channel
- 14.8.3. Mexico Systemic Scleroderma Treatment Market
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Target Organ
    - 14.8.3.2.2. By Therapy Type
    - 14.8.3.2.3. By Route of Administration
    - 14.8.3.2.4. By Distribution Channel

15. Europe Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. BENELUX
  - 15.3.1.7. Russia
  - 15.3.1.8. Rest of Europe
- 15.3.2. By Target Organ
- 15.3.3. By Therapy Type
- 15.3.4. By Route of Administration
- 15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Target Organ
- 15.4.3. By Therapy Type
- 15.4.4. By Route of Administration
- 15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Systemic Scleroderma Treatment Market
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Target Organ
    - 15.8.1.2.2. By Therapy Type
    - 15.8.1.2.3. By Route of Administration
    - 15.8.1.2.4. By Distribution Channel
- 15.8.2. France Systemic Scleroderma Treatment Market
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Target Organ
    - 15.8.2.2.2. By Therapy Type
    - 15.8.2.2.3. By Route of Administration
    - 15.8.2.2.4. By Distribution Channel
- 15.8.3. Italy Systemic Scleroderma Treatment Market
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Target Organ
    - 15.8.3.2.2. By Therapy Type
    - 15.8.3.2.3. By Route of Administration
    - 15.8.3.2.4. By Distribution Channel
- 15.8.4. Spain Systemic Scleroderma Treatment Market
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Target Organ
    - 15.8.4.2.2. By Therapy Type
    - 15.8.4.2.3. By Route of Administration
    - 15.8.4.2.4. By Distribution Channel
- 15.8.5. U.K. Systemic Scleroderma Treatment Market
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.5.2.1. By Target Organ
    - 15.8.5.2.2. By Therapy Type
    - 15.8.5.2.3. By Route of Administration
    - 15.8.5.2.4. By Distribution Channel
- 15.8.6. Benelux Union Systemic Scleroderma Treatment Market
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.6.2.1. By Target Organ
    - 15.8.6.2.2. By Therapy Type
    - 15.8.6.2.3. By Route of Administration
    - 15.8.6.2.4. By Distribution Channel
- 15.8.7. Russia Systemic Scleroderma Treatment Market
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.7.2.1. By Target Organ
    - 15.8.7.2.2. By Therapy Type
    - 15.8.7.2.3. By Route of Administration
    - 15.8.7.2.4. By Distribution Channel

16. South Asia Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Thailand
  - 16.3.1.3. Indonesia
  - 16.3.1.4. Malaysia
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Target Organ
- 16.3.3. By Therapy Type
- 16.3.4. By Route of Administration
- 16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Target Organ
- 16.4.3. By Therapy Type
- 16.4.4. By Route of Administration
- 16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. India Systemic Scleroderma Treatment Market
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Target Organ
    - 16.8.1.2.2. By Therapy Type
    - 16.8.1.2.3. By Route of Administration
    - 16.8.1.2.4. By Distribution Channel
- 16.8.2. Indonesia Systemic Scleroderma Treatment Market
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Target Organ
    - 16.8.2.2.2. By Therapy Type
    - 16.8.2.2.3. By Route of Administration
    - 16.8.2.2.4. By Distribution Channel
- 16.8.3. Malaysia Systemic Scleroderma Treatment Market
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Target Organ
    - 16.8.3.2.2. By Therapy Type
    - 16.8.3.2.3. By Route of Administration
    - 16.8.3.2.4. By Distribution Channel
- 16.8.4. Thailand Systemic Scleroderma Treatment Market
  - 16.8.4.1. Introduction
  - 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.4.2.1. By Target Organ
    - 16.8.4.2.2. By Therapy Type
    - 16.8.4.2.3. By Route of Administration
    - 16.8.4.2.4. By Distribution Channel

17. East Asia Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 17.3.1. By Country
  - 17.3.1.1. China
  - 17.3.1.2. Japan
  - 17.3.1.3. South Korea
- 17.3.2. By Target Organ
- 17.3.3. By Therapy Type
- 17.3.4. By Route of Administration
- 17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Target Organ
- 17.4.3. By Therapy Type
- 17.4.4. By Route of Administration
- 17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. China Systemic Scleroderma Treatment Market
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Target Organ
    - 17.8.1.2.2. By Therapy Type
    - 17.8.1.2.3. By Route of Administration
    - 17.8.1.2.4. By Distribution Channel
- 17.8.2. Japan Systemic Scleroderma Treatment Market
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Target Organ
    - 17.8.2.2.2. By Therapy Type
    - 17.8.2.2.3. By Route of Administration
    - 17.8.2.2.4. By Distribution Channel
- 17.8.3. South Korea Systemic Scleroderma Treatment Market
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Target Organ
    - 17.8.3.2.2. By Therapy Type
    - 17.8.3.2.3. By Route of Administration
    - 17.8.3.2.4. By Distribution Channel

18. Oceania Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Target Organ
- 18.3.3. By Therapy Type
- 18.3.4. By Route of Administration
- 18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Target Organ
- 18.4.3. By Therapy Type
- 18.4.4. By Route of Administration
- 18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Systemic Scleroderma Treatment Market
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Target Organ
    - 18.8.1.2.2. By Therapy Type
    - 18.8.1.2.3. By Route of Administration
    - 18.8.1.2.4. By Distribution Channel
- 18.8.2. New Zealand Systemic Scleroderma Treatment Market
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Target Organ
    - 18.8.2.2.2. By Therapy Type
    - 18.8.2.2.3. By Route of Administration
    - 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Israel
  - 19.3.1.3. Turkey
  - 19.3.1.4. North Africa
  - 19.3.1.5. South Africa
  - 19.3.1.6. Rest of Middle East and Africa
- 19.3.2. By Target Organ
- 19.3.3. By Therapy Type
- 19.3.4. By Route of Administration
- 19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By Target Organ
- 19.4.3. By Therapy Type
- 19.4.4. By Route of Administration
- 19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Systemic Scleroderma Treatment Market
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.1.2.1. By Target Organ
    - 19.8.1.2.2. By Therapy Type
    - 19.8.1.2.3. By Route of Administration
    - 19.8.1.2.4. By Distribution Channel
- 19.8.2. Turkey Systemic Scleroderma Treatment Market
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.2.2.1. By Target Organ
    - 19.8.2.2.2. By Therapy Type
    - 19.8.2.2.3. By Route of Administration
    - 19.8.2.2.4. By Distribution Channel
- 19.8.3. South Africa Systemic Scleroderma Treatment Market
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.3.2.1. By Target Organ
    - 19.8.3.2.2. By Therapy Type
    - 19.8.3.2.3. By Route of Administration
    - 19.8.3.2.4. By Distribution Channel
- 19.8.4. North Africa Systemic Scleroderma Treatment Market
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.4.2.1. By Target Organ
    - 19.8.4.2.2. By Therapy Type
    - 19.8.4.2.3. By Route of Administration
    - 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis, By Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. Pfizer Inc.
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Key Financials
  - 21.3.1.4. SWOT Analysis
  - 21.3.1.5. Strategy Overview
  - 21.3.1.6. Key Developments
- 21.3.2. Novartis AG
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Key Financials
  - 21.3.2.4. SWOT Analysis
  - 21.3.2.5. Strategy Overview
  - 21.3.2.6. Key Developments
- 21.3.3. GlaxoSmithKline plc.
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Key Financials
  - 21.3.3.4. SWOT Analysis
  - 21.3.3.5. Strategy Overview
  - 21.3.3.6. Key Developments
- 21.3.4. Sanofi SA
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Key Financials
  - 21.3.4.4. SWOT Analysis
  - 21.3.4.5. Strategy Overview
  - 21.3.4.6. Key Developments
- 21.3.5. Lupin Ltd
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Key Financials
  - 21.3.5.4. SWOT Analysis
  - 21.3.5.5. Strategy Overview
  - 21.3.5.6. Key Developments
- 21.3.6. Cipla Ltd
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Key Financials
  - 21.3.6.4. SWOT Analysis
  - 21.3.6.5. Strategy Overview
  - 21.3.6.6. Key Developments
- 21.3.7. Teva Pharmaceuticals
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Key Financials
  - 21.3.7.4. SWOT Analysis
  - 21.3.7.5. Strategy Overview
  - 21.3.7.6. Key Developments
- 21.3.8. Johnson & Johnson Services Inc.
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Key Financials
  - 21.3.8.4. SWOT Analysis
  - 21.3.8.5. Strategy Overview
  - 21.3.8.6. Key Developments
- 21.3.9. Bayer Healthcare LLC
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Key Financials
  - 21.3.9.4. SWOT Analysis
  - 21.3.9.5. Strategy Overview
  - 21.3.9.6. Key Developments
- 21.3.10. F. Hoffmann-La Roche Ltd
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Key Financials
  - 21.3.10.4. SWOT Analysis
  - 21.3.10.5. Strategy Overview
  - 21.3.10.6. Key Developments
- 21.3.11. Amgen Inc
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. Key Financials
  - 21.3.11.4. SWOT Analysis
  - 21.3.11.5. Strategy Overview
  - 21.3.11.6. Key Developments
- 21.3.12. Zydus Lifesciences Ltd
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. Key Financials
  - 21.3.12.4. SWOT Analysis
  - 21.3.12.5. Strategy Overview
  - 21.3.12.6. Key Developments
- 21.3.13. Casper Pharma
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. Key Financials
  - 21.3.13.4. SWOT Analysis
  - 21.3.13.5. Strategy Overview
  - 21.3.13.6. Key Developments
- 21.3.14. Boehringer Ingelheim Pharmaceuticals, Inc
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. Key Financials
  - 21.3.14.4. SWOT Analysis
  - 21.3.14.5. Strategy Overview
  - 21.3.14.6. Key Developments
- 21.3.15. Organon LLC
  - 21.3.15.1. Overview
  - 21.3.15.2. Product Portfolio
  - 21.3.15.3. Key Financials
  - 21.3.15.4. SWOT Analysis
  - 21.3.15.5. Strategy Overview
  - 21.3.15.6. Key Developments
- 21.3.16. Accord Healthcare Inc
  - 21.3.16.1. Overview
  - 21.3.16.2. Product Portfolio
  - 21.3.16.3. Key Financials
  - 21.3.16.4. SWOT Analysis
  - 21.3.16.5. Strategy Overview
  - 21.3.16.6. Key Developments